Related references
Note: Only part of the references are listed.Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension
Magdalena Malm et al.
BIOTECHNOLOGY JOURNAL (2014)
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sorensen et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo
Feifan Yu et al.
MABS (2014)
Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein
Anna Orlova et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity
Hye-Ji Choi et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Monoclonal antibody therapeutics with up to five specificities Functional enhancement through fusion of target-specific peptides
David W. LaFleur et al.
MABS (2013)
Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth
Mahdi Behdani et al.
NEW BIOTECHNOLOGY (2013)
Penetration of a Topically Administered Anti-Tumor Necrosis Factor Alpha Antibody Fragment into the Anterior Chamber of the Human Eye
Michael A. Thiel et al.
OPHTHALMOLOGY (2013)
Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
Magdalena Malm et al.
PLOS ONE (2013)
Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization
Maurice S. Brozzo et al.
BLOOD (2012)
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
Kuifeng He et al.
ONCOTARGETS AND THERAPY (2012)
Imaging biomarkers of brain tumour margin and tumour invasion
S. J. Price et al.
BRITISH JOURNAL OF RADIOLOGY (2011)
Basic and Therapeutic Aspects of Angiogenesis
Michael Potente et al.
CELL (2011)
Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2011)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
Sonia Tugues et al.
MOLECULAR ASPECTS OF MEDICINE (2011)
Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and αvβ3 integrin
Niv Papo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules
Nina Kronqvist et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours
Anna Orlova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount
Vladimir Tolmachev et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
J. Lofblom et al.
FEBS LETTERS (2010)
Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors
Helena Wallberg et al.
MOLECULAR IMAGING AND BIOLOGY (2010)
The VEGF family in cancer and antibody-based strategies for their inhibition
Laura A. Sullivan et al.
MABS (2010)
Antibody Vectors for Imaging
Tove Olafsen et al.
SEMINARS IN NUCLEAR MEDICINE (2010)
Slow internalization of anti-HER2 synthetic Affibody monomer 111In-DOTA-ZHER2:342-pep2:: Implications for development of labeled tracers
Helena Wallberg et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2008)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
Junji Matsui et al.
CLINICAL CANCER RESEARCH (2008)
A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry
Nina Kronqvist et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2008)
Engineering of a femtomolar affinity binding protein to human serum albumin
Andreas Jonsson et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2008)
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology:: tools or decorations?
Cristiana Sessa et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Robert Roskoski
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Optimization of electroporation-mediated transformation:: Staphylococcus carnosus as model organism
J. Lofblom et al.
JOURNAL OF APPLIED MICROBIOLOGY (2007)
Selection and characterization of affibody ligands binding to Alzheimer amyloid β peptides
Caroline Gronwall et al.
JOURNAL OF BIOTECHNOLOGY (2007)
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts
Anthony Polverino et al.
CANCER RESEARCH (2006)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Single variable domain-IgG fusion - A novel recombinant approach to Fc domain-containing bispecific antibodies
JQ Shen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Tumor Imaging using a picomolar affinity HER2 binding affibody molecule
A Orlova et al.
CANCER RESEARCH (2006)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy
D Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
